Myleran

Active Ingredient(s): Busulfan
FDA Approved: * June 26, 1954
Pharm Company: * GLAXOSMITHKLINE
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Myleran Overview

Busulfan (Myleran, GlaxoSmithKline, Busulfex IV, Otsuka America Pharmaceutical, Inc.) is a cancer drug, in use since 1959. Busulfan is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Its chemical designation is 1,4-butanediol dimethanesulfonate. Contents 1 History 2 Indications 3 Availability 4 Side effects 5 Dosing, administration, and pharmacokinetics 6 Drug interactions 7 Pharmacology 8 Complexation 9 References 10 External links Histor...

Read more Myleran Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Busulfan

Recent Myleran Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Myleran: (2 results)

Sorted by National Drug Code

• 0173-0713 Myleran 2 mg Oral Tablet by Glaxosmithkline LLC
• 76388-713 Myleran 2 mg Oral Tablet by Aspen Global Inc.

Other drugs which contain Busulfan or a similar ingredient: (2 results)

• BUSULFAN
• BUSULFEX Busulfan